| Autor: |
Linhui Hao, Tien-Ying Hsiang, Ronit R. Dalmat, Renee Ireton, Jennifer Morton, Caleb Stokes, Jason Netland, Malika Hale, Chris Thouvenel, Anna Wald, Nicholas M Franko, Kristen Huden, Helen Chu, Alex Greninger, Sasha Tilles, Lynn K. Barrett, Wesley C. Van Voorhis, Jennifer Munt, Trevor Scobey, Ralph S. Baric, David Rawlings, Marion Pepper, Paul K. Drain, Michael Gale |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
medRxiv |
| Popis: |
To evaluate SARS-CoV-2 variants we isolated SARS-CoV-2 temporally during the pandemic starting with first appearance of virus in the Western hemisphere near Seattle, WA, USA, and isolated each known major variant class, revealing the dynamics of emergence and complete take-over of all new cases by current Omicron variants. We assessed virus neutralization in a first-ever full comparison across variants and evaluated a novel monoclonal antibody (Mab). We found that convalescence greater than 5-months provides little-to-no protection against SARS-CoV-2 variants, vaccination enhances immunity against variants with the exception of Omicron BA.1, and paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50-fold enhanced protection against Omicron BA.1 compared to a 2-dose regimen. We also reveal a novel Mab that effectively neutralizes Omicron BA.1 and BA.2 variants over clinically-approved Mabs. Our observations underscore the need for continued vaccination efforts, with innovation for vaccine and Mab improvement, for protection against variants of SARS-CoV-2.SummaryWe isolated SARS-CoV-2 temporally starting with emergence of virus in the Western hemisphere. Neutralization analyses across all variant lineages show that vaccine-boost regimen provides protection against Omicron BA.1. We reveal a Mab that protects against Omicron BA.1 and BA.2 variants. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
